4.2 Article

Pulmonary Hypertension in Parenchymal Lung Disease

Journal

HEART FAILURE CLINICS
Volume 8, Issue 3, Pages 461-+

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.hfc.2012.04.010

Keywords

Pulmonary hypertension; Interstitial lung disease; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis

Funding

  1. F32 training grant [NIH 5T32HL098040-01]
  2. Gilead
  3. United Therapeutics
  4. Pfizer
  5. Novartis
  6. Bayer
  7. GeNO

Ask authors/readers for more resources

The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available